Reckitt Benckiser Pharms., Inc. v. Biodelivery Services Ltd. (E.D.N.C.)

by Robins Kaplan LLP

Case Name: Reckitt Benckiser Pharms., Inc. v. Biodelivery Services Ltd., Case No. 5:13-CV-760-TWB, 2014 U.S. Dist. LEXIS 69805 (E.D.N.C. May 20, 2014) (Boyle, J.) 

Drug Product and Patent(s)-in-Suit: Suboxone® (buprenorphine); U.S. Pat. No. 8,475,832 (“the ’832 patent”)

Nature of the Case and Issue(s) Presented: The issues presented were whether defendant’s actions were sufficient to support declaratory judgment jurisdiction and whether defendant’s conduct supports a claim for patent infringement under 35 U.S.C. § 271(e)(4).

Reckitt Benckiser (“RB”) owns the ’832 patent, which covers sublingual and buccal film compositions used in the treatment of opioid dependence. Those compositions are marketed as Suboxone. RB owns two NDAs covering Suboxone: one covers sublingual film delivery and the other covers a tablet version of the drug.

Biodelivery Services (“Biodelivery”) filed its own NDA seeking approval to manufacture and sell a drug called Bunavail®, which is also an orally-administered mucoadhesive formulation designed to treat opioid dependency. RB filed suit, seeking declaratory judgment that the drug described in Biodelivery’s NDA is infringed by one or more claims of the ’832 patent. In its second count, RB alleges that Biodelivery’s submission of its NDA is an act of infringement under 35 U.S.C. § 271(e)(4). Biodelivery moved to dismiss count one of the complaint under Fed. R. Civ. P. 12(b)(1) for lack of subject matter jurisdiction. Biodelivery also moved to dismiss count two under Fed. R. Civ. P. 12(b)(6) for failure to state a claim upon which relief can be granted. The court granted both of Biodelivery’s motions.

Why Biodelivery Prevailed:  RB filed its complaint on October 29, 2013. Biodelivery filed its NDA in July 2013. The court noted that at the time it considered the issue, the FDA still had not acted on the Biodelivery’s NDA. RB argued that this fact was irrelevant because Biodelivery had announced its intent to market Bunavail once it had obtained the FDA’s approval. But the court noted that RB’s claim rested on two completely contingent events: (i) eventual FDA approval of Biodelivery’s NDA; and (ii) Biodelivery’s decision to market its drug pursuant to that NDA. The court also noted that any actions Biodelivery had taken to date, such as research and development, were protected by the safe harbor provision of 35 U.S.C. § 271(e)(1). Last, the court indicated that infringement allegations could be based on evidence that the alleged future infringer had engaged in marketing or solicited orders for its product, but RB had produced no such proof. RB did provide evidence that Biodelivery included information about the new drug in its annual report, and had issued a press release in relation to its NDA, but the court did not find this evidence persuasive. Accordingly, the court granted Biodelivery’s motion to dismiss count one of the complaint, based on a lack of subject matter jurisdiction.

Next, the court considered RB’s argument that the filing of Biodelivery’s NDA constituted an artificial act of infringement under 35 U.S.C. § 271(e)(2). Biodelivery filed its NDA pursuant to 21 U.S.C. § 505(b)(2), which covers NDAs where a listed drug is similar to the new drug. Unlike an applicant for a generic drug, a 505(b)(2) applicant is permitted to choose the most appropriate listed drug for reference, and is not required to choose the most similar listed drug. The applicant must also make one of four certifications: (i) that no patent information has been filed; (ii) that the patent has expired; (iii) that the patent will expire on a specific date; or (iv) that the patent is invalid or will not be infringed by the manufacture, use, or sale of the drug for which the application is submitted. In its application, Biodelivery selected Suboxone® sublingual tablets as the reference drug (as opposed to the film whose formulation was covered by the claims of the ’832 patent). Biodelivery also did not file a paragraph IV certification as part of its application. Because § 271(e)(2) clearly defines an infringing act as filing an ANDA for a drug claimed in a patent or the use of which is claimed in a patent, the Court determined that it was not applicable. In the absence of a paragraph IV certification, RB’s count two was dismissed for failure to state a claim upon which relief could be based.

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Robins Kaplan LLP | Attorney Advertising

Written by:

Robins Kaplan LLP

Robins Kaplan LLP on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up using*

Already signed up? Log in here

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
Privacy Policy (Updated: October 8, 2015):

JD Supra provides users with access to its legal industry publishing services (the "Service") through its website (the "Website") as well as through other sources. Our policies with regard to data collection and use of personal information of users of the Service, regardless of the manner in which users access the Service, and visitors to the Website are set forth in this statement ("Policy"). By using the Service, you signify your acceptance of this Policy.

Information Collection and Use by JD Supra

JD Supra collects users' names, companies, titles, e-mail address and industry. JD Supra also tracks the pages that users visit, logs IP addresses and aggregates non-personally identifiable user data and browser type. This data is gathered using cookies and other technologies.

The information and data collected is used to authenticate users and to send notifications relating to the Service, including email alerts to which users have subscribed; to manage the Service and Website, to improve the Service and to customize the user's experience. This information is also provided to the authors of the content to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

JD Supra does not sell, rent or otherwise provide your details to third parties, other than to the authors of the content on JD Supra.

If you prefer not to enable cookies, you may change your browser settings to disable cookies; however, please note that rejecting cookies while visiting the Website may result in certain parts of the Website not operating correctly or as efficiently as if cookies were allowed.

Email Choice/Opt-out

Users who opt in to receive emails may choose to no longer receive e-mail updates and newsletters by selecting the "opt-out of future email" option in the email they receive from JD Supra or in their JD Supra account management screen.


JD Supra takes reasonable precautions to insure that user information is kept private. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. However, please note that no method of transmitting or storing data is completely secure and we cannot guarantee the security of user information. Unauthorized entry or use, hardware or software failure, and other factors may compromise the security of user information at any time.

If you have reason to believe that your interaction with us is no longer secure, you must immediately notify us of the problem by contacting us at In the unlikely event that we believe that the security of your user information in our possession or control may have been compromised, we may seek to notify you of that development and, if so, will endeavor to do so as promptly as practicable under the circumstances.

Sharing and Disclosure of Information JD Supra Collects

Except as otherwise described in this privacy statement, JD Supra will not disclose personal information to any third party unless we believe that disclosure is necessary to: (1) comply with applicable laws; (2) respond to governmental inquiries or requests; (3) comply with valid legal process; (4) protect the rights, privacy, safety or property of JD Supra, users of the Service, Website visitors or the public; (5) permit us to pursue available remedies or limit the damages that we may sustain; and (6) enforce our Terms & Conditions of Use.

In the event there is a change in the corporate structure of JD Supra such as, but not limited to, merger, consolidation, sale, liquidation or transfer of substantial assets, JD Supra may, in its sole discretion, transfer, sell or assign information collected on and through the Service to one or more affiliated or unaffiliated third parties.

Links to Other Websites

This Website and the Service may contain links to other websites. The operator of such other websites may collect information about you, including through cookies or other technologies. If you are using the Service through the Website and link to another site, you will leave the Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We shall have no responsibility or liability for your visitation to, and the data collection and use practices of, such other sites. This Policy applies solely to the information collected in connection with your use of this Website and does not apply to any practices conducted offline or in connection with any other websites.

Changes in Our Privacy Policy

We reserve the right to change this Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our privacy policy will become effective upon posting of the revised policy on the Website. By continuing to use the Service or Website following such changes, you will be deemed to have agreed to such changes. If you do not agree with the terms of this Policy, as it may be amended from time to time, in whole or part, please do not continue using the Service or the Website.

Contacting JD Supra

If you have any questions about this privacy statement, the practices of this site, your dealings with this Web site, or if you would like to change any of the information you have provided to us, please contact us at:

- hide
*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.